Q-omics provides the consensus-scored GNG12 profile across patient tissues and cancer cell-line models. GNG12 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GNG12 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, GNG12 protein abundance shows 22,803 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, COAD, and PDAC as cancer lineages where GNG12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GNG12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GNG12 survival associations across molecular data types. GNG12 RNA expression shows survival associations in the most cancer types (28), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GNG12 RNA expression–survival associations across cancer types. High GNG12 expression shows unfavorable associations in ACC, MESO and LGG, but favorable associations in KIRC, COAD and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GNG12 RNA expression.
This table summarizes GNG12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for GNG12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GNG12 shows lower tumor expression in COAD, KICH, UCEC, BRCA and THCA and higher tumor expression in HNSC. The COAD box plot shows higher GNG12 RNA expression in normal versus tumor tissue (log2 FC = −1.356, t-test p < 0.001).
This table shows molecular features associated with GNG12 in patient tissues and cancer cell lines. In patient samples, GNG12 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, GNG12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SKIN.
